Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Galapagos NV GLPG
$40.64
-$0.52 (-1.29%)
На 18:00, 12 мая 2023
+118.73%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2714960520.00000000
-
week52high
60.01
-
week52low
36.17
-
Revenue
505280000
-
P/E TTM
-35
-
Beta
0.06259500
-
EPS
-3.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 04:00
Описание компании
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 15 авг 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 08 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 15 июл 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 09 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 28 февр 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 09 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 13 окт 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 07 ноя 2022 г. |
| Raymond James | Market Perform | Outperform | 07 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 07 ноя 2022 г. |
| Jefferies | Hold | Underperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Galapagos Stands Strong On Jyseleca Positive Clinical Data
Seeking Alpha
06 мая 2023 г. в 01:59
Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy data presented from ongoing Phase 1/2 studies.
Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript
Seeking Alpha
24 февр 2023 г. в 10:35
Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D'Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voorthuizen - Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast.
Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
Seeking Alpha
11 февр 2023 г. в 07:07
On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory.
Galapagos shares down after announcing clinical-trial miss for Crohn's disease
Market Watch
09 февр 2023 г. в 08:35
U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 16:01
Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .